EMMA - Emmaus strikes deal with Kainos Medicine in anti-cancer drug development

Emmaus Life Sciences ([[EMMA]]) announces that it has entered into an agreement with Kainos Medicine to lead the preclinical development of its patented IRAK4 inhibitor (KM10544) as an anti-cancer drug.Kainos will receive $500K in cash and $500K in Emmaus shares for entering into the agreement.Kainos plans to complete the study of the therapeutic mechanism of action of KM10544 in solid cancers, blood cancers and lymphoma. Emmaus will be responsible for the investigation and proof of target disease selection, efficacy and safety.The companies have also entered into a letter of intent for possible future joint development of small molecule therapeutics and other pharmaceutical assets.

For further details see:

Emmaus strikes deal with Kainos Medicine in anti-cancer drug development